CRNA Stock Overview
A biotechnology company, develops novel circular RNA and immunotherapy medicines. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Circio Holding ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 0.73 |
| 52 Week High | NOK 13.20 |
| 52 Week Low | NOK 0.54 |
| Beta | 1.61 |
| 11 Month Change | 7.67% |
| 3 Month Change | -44.49% |
| 1 Year Change | -89.79% |
| 33 Year Change | -99.37% |
| 5 Year Change | -99.51% |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Circio Holding ASA's (OB:CRNA) CEO Will Probably Struggle To See A Pay Rise This Year
May 29
Targovax ASA's (OB:TRVX) Intrinsic Value Is Potentially 96% Above Its Share Price
Aug 24Health Check: How Prudently Does Targovax (OB:TRVX) Use Debt?
Jul 08Is Targovax (OB:TRVX) Using Debt In A Risky Way?
Oct 27Is Targovax (OB:TRVX) A Risky Investment?
Jul 05Shareholders May Be A Bit More Conservative With Targovax ASA's (OB:TRVX) CEO Compensation For Now
Mar 10Is Targovax (OB:TRVX) Using Debt In A Risky Way?
Feb 20The Chief Scientific Officer of Targovax ASA (OB:TRVX), Victor Levitsky, Just Bought A Few More Shares
Dec 05
Shareholder Returns
| CRNA | NO Biotechs | NO Market | |
|---|---|---|---|
| 7D | -14.1% | 8.9% | 3.1% |
| 1Y | -89.8% | -69.4% | 3.9% |
Return vs Industry: CRNA underperformed the Norwegian Biotechs industry which returned -70.5% over the past year.
Return vs Market: CRNA underperformed the Norwegian Market which returned 2.5% over the past year.
Price Volatility
| CRNA volatility | |
|---|---|
| CRNA Average Weekly Movement | 84.9% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in NO Market | 10.6% |
| 10% least volatile stocks in NO Market | 2.7% |
Stable Share Price: CRNA's share price has been volatile over the past 3 months compared to the Norwegian market.
Volatility Over Time: CRNA's weekly volatility has increased from 48% to 85% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 8 | Erik Wiklund | www.circio.com |
Circio Holding ASA, a biotechnology company, develops novel circular RNA and immunotherapy medicines. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells. The company was formerly known as Targovax ASA and changed its name to Circio Holding ASA in May 2023.
Circio Holding ASA Fundamentals Summary
| CRNA fundamental statistics | |
|---|---|
| Market cap | NOK 30.64m |
| Earnings (TTM) | NOK 9.50m |
| Revenue (TTM) | NOK 123.00k |
3.2x
P/E Ratio249.1x
P/S RatioIs CRNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRNA income statement (TTM) | |
|---|---|
| Revenue | NOK 123.00k |
| Cost of Revenue | NOK 0 |
| Gross Profit | NOK 123.00k |
| Other Expenses | -NOK 9.38m |
| Earnings | NOK 9.50m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.23 |
| Gross Margin | 100.00% |
| Net Profit Margin | 7,722.76% |
| Debt/Equity Ratio | -81.1% |
How did CRNA perform over the long term?
See historical performance and comparison